Roxana Mehran,

Search results

• CeloNova announces interim results from randomized controlled trial evaluating 14-days DAPT in complex patients at high bleeding risk following PCI

  Roxana Mehran,

  20/10/20

  1 item of Media coverage

  Press/Media

• United States : New Late-breaking Data Show Equivalent Outcomes With Shorter Durations Of Anti-clotting Drugs For Xience Stent Patients With High Bleeding Risk

  Roxana Mehran,

  19/10/20

  1 item of Media coverage

  Press/Media

• CeloNova Announces Late-Breaking Evidence From First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT In Complex Patients At High Bleeding Risk Following PCI

  Roxana Mehran,

  17/10/20 → 19/10/20

  2 items of Media coverage

  Press/Media

• TCT Connect 2020: CeloNova announces interim data from 14-day DAPT trial

  Roxana Mehran,

  18/10/20

  1 item of Media coverage

  Press/Media

• CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

  Roxana Mehran,

  17/10/20 → 18/10/20

  12 items of Media coverage

  Press/Media

• CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI; The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days D

  Roxana Mehran,

  17/10/20

  2 items of Media coverage

  Press/Media

• Abbott announces new late-breaking data show equivalent outcomes with shorter durations of anti-clotting drugs for Xience stent patients with high bleeding risk

  Roxana Mehran,

  17/10/20

  1 item of Media coverage

  Press/Media

• Shorter DAPT With Xience Stent is Noninferior to Standard DAPT

  Roxana Mehran,

  16/10/20

  1 item of Media coverage

  Press/Media

• -ABBOTT - NEW LATE-BREAKING DATA SHOW EQUIVALENT OUTCOMES WITH SHORTER DURATIONS OF ANTI-CLOTTING DRUGS FOR XIENCE STENT PATIENTS WITH HIGH BLEEDING RISK

  Roxana Mehran,

  16/10/20

  1 item of Media coverage

  Press/Media

• FFR Insights Before and After PCI: Fresh Food for Thought

  Roxana Mehran,

  16/10/20

  1 item of Media coverage

  Press/Media

• More Support for Shorter DAPT in High Bleeding Risk PCI

  Roxana Mehran,

  16/10/20

  1 item of Media coverage

  Press/Media

• New Late-Breaking Data Show Equivalent Outcomes with Shorter Durations of Anti-Clotting Drugs for XIENCE™ Stent Patients with High Bleeding Risk

  Roxana Mehran,

  15/10/20

  3 items of Media coverage

  Press/Media

• Ticagrelor Monotherapy Beats DAPT in STEMI

  Roxana Mehran,

  15/10/20

  2 items of Media coverage

  Press/Media

• Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

  Roxana Mehran,

  15/10/20

  1 item of Media coverage

  Press/Media

• Ticagrelor monotherapy reduces bleeding, does not impact ischemia after PCI for STEMI

  Roxana Mehran,

  14/10/20

  1 item of Media coverage

  Press/Media

• ‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

  Roxana Mehran,

  16/09/20

  1 item of Media coverage

  Press/Media

• TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

  Roxana Mehran,

  17/06/20

  1 item of Media coverage

  Press/Media

• Cautions Raised Against Off-Label DOACs to Clear LV Thrombi

  Roxana Mehran,

  28/04/20

  1 item of Media coverage

  Press/Media

• Off-Label DOAC Use Not Appropriate for LV Thrombi, Increases Stroke Risk

  Roxana Mehran,

  24/04/20

  2 items of Media coverage

  Press/Media

• Study: Off-Label Use of DOACs Worrisome for LV Thrombi

  Roxana Mehran,

  22/04/20

  2 items of Media coverage

  Press/Media

• BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

  Roxana Mehran,

  29/03/20 → 31/03/20

  30 items of Media coverage

  Press/Media

• -AstraZeneca - Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

  Roxana Mehran,

  31/03/20

  1 item of Media coverage

  Press/Media

• COVID-19: TCTMD’s Daily Dispatch for March 30

  Gennaro Giustino & Roxana Mehran,

  30/03/20

  1 item of Media coverage

  Press/Media

• AstraZeneca: Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

  Roxana Mehran,

  30/03/20

  1 item of Media coverage

  Press/Media

• BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial; BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percu

  Roxana Mehran,

  30/03/20

  1 item of Media coverage

  Press/Media